Anti-TAZ antibody [EPR25084-93]
- 20ul selling size
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(2 Publications)
Rabbit Recombinant Monoclonal TAZ antibody. Suitable for IP, WB and reacts with Mouse, Human samples. Cited in 2 publications.
View Alternative Names
TAZ, WWTR1, WW domain-containing transcription regulator protein 1, Transcriptional coactivator with PDZ-binding motif
- IP
Supplier Data
Immunoprecipitation - Anti-TAZ antibody [EPR25084-93] (AB307440)
TAZ was immunoprecipitated from 0.35 mg NIH/3T3 (mouse embryonic fibroblast) whole cell lysate 10 µg with ab307440 at 1/30 dilution (2µg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab307440 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution. Lane 1 : NIH/3T3 (mouse embryonic fibroblast) whole cell lysate 10 µg Lane 2 : ab307440 IP in NIH/3T3 whole cell lysate Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab307440 in NIH/3T3 whole cell lysate Blocking and dilution buffer and concentration : 5% NFDM/TBST. Exposure time : 93 seconds
- WB
Supplier Data
Western blot - Anti-TAZ antibody [EPR25084-93] (AB307440)
Blocking and diluting buffer and concentration : 5% NFDM/TBST. Negative control : Raji. Low expression : SH-SY5Y (PMID : 26104008) . Exposure time : 59 seconds.
All lanes:
Western blot - Anti-TAZ antibody [EPR25084-93] (ab307440) at 1/1000 dilution
Lane 1:
SK-MEL-28 (human malignant melanoma cell) whole cell lysate at 20 µg
Lane 2:
SH-SY5Y (human neuroblastoma epithelial cell) whole cell lysate at 20 µg
Lane 3:
Raji (human Burkitts lymphoma B lymphocyte) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Observed band size: 50 kDa
false
Exposure time: 59s
- WB
Supplier Data
Western blot - Anti-TAZ antibody [EPR25084-93] (AB307440)
Blocking and diluting buffer and concentration : 5% NFDM/TBST.
This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.
All lanes:
Western blot - Anti-TAZ antibody [EPR25084-93] (ab307440) at 1/1000 dilution
Lane 1:
HeLa (human cervix adenocarcinoma epithelial cell) transfected with scrambled siRNA control whole cell lysate at 20 µg
Lane 2:
HeLa transfected with siRNA specifically targeting TAZ whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Observed band size: 37 kDa
true
Exposure time: 37s
- WB
Supplier Data
Western blot - Anti-TAZ antibody [EPR25084-93] (AB307440)
Blocking and diluting buffer and concentration : 5% NFDM/TBST.
This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.
All lanes:
Western blot - Anti-TAZ antibody [EPR25084-93] (ab307440) at 1/1000 dilution
All lanes:
NIH/3T3 (mouse embryonic fibroblast) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Observed band size: 50 kDa
true
Exposure time: 180s
- WB
Supplier Data
Western blot - Anti-TAZ antibody [EPR25084-93] (AB307440)
Blocking and diluting buffer and concentration : 5% NFDM/TBST. The bands beneath the target band (50 kDa) may represent degraded target fragments . Exposure time : 59 seconds.
All lanes:
Western blot - Anti-TAZ antibody [EPR25084-93] (ab307440) at 1/1000 dilution
All lanes:
C2C12 (mouse myoblasts myoblast) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Observed band size: 50 kDa
false
Exposure time: 59s
Related conjugates and formulations (1)
-
Anti-TAZ antibody [EPR25084-93] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
TAZ works as a part of the Hippo signaling pathway regulating cell growth proliferation and apoptosis. It changes cellular responses through interactions with other proteins such as TEAD transcription factors. TAZ can act within the cytoplasm or the nucleus changing its location in the cell based on physiological signals. It operates independently as well as in concert with other molecules assisting in maintaining tissue homeostasis and regeneration.
Pathways
TAZ functions as an essential element of the Hippo pathway which controls organ size and suppresses cancer. It plays significant roles in the PI3K-AKT signaling pathway coordinating with YAP (Yes-associated protein) a well-known partner in these pathways. TAZ and YAP together influence transcriptional outcomes for numerous genes adjusting to the needs of various cellular contexts which affect cell behavior significantly.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (2)
Recent publications for all applications. Explore the full list and refine your search
Journal of thoracic disease 16:7709-7728 PubMed39678869
2024
Applications
Unspecified application
Species
Unspecified reactive species
Anti-cancer drugs 35:902-911 PubMed39012720
2024
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com